The new COO joins StimAire to advance the development of its injectable neurostimulator for obstructive sleep apnea.
Summary:
StimAire, a company developing an injectable neurostimulator to treat obstructive sleep apnea (OSA), has appointed Arthur Rascon as its new chief operating officer (COO). Rascon brings over two decades of experience in the medical device industry, having previously held leadership positions at Valencia Technologies Corp, Medtronic Diabetes, and Advanced Bionics. StimAire aims to advance its technology from a demonstrated concept to a certified medical device, leveraging Rascon’s expertise to achieve this goal.
Key Takeaways:
- New Leadership: StimAire has appointed an industry veteran with over 20 years of experience as COO to drive the development of its injectable neurostimulator for OSA.
- Experienced Background: The new COO has a proven track record in the medical device industry, including leadership roles at Valencia Technologies, Medtronic Diabetes, and Advanced Bionics.
- Development Milestones: StimAire has recently completed its first-in-human study and received Breakthrough Device Designation from the FDA.
StimAire, which is developing an injectable neurostimulator to treat obstructive sleep apnea, has appointed Arthur Rascon as chief operating officer.
Rascon brings over two decades of experience in operational leadership and a track record of driving innovation and commercialization in the medical device industry. Prior to joining StimAire, Rascon served as the chief executive officer at Valencia Technologies Corp, where he led the company’s neuromodulation therapies.
Before Valencia Technologies, he was senior director of manufacturing engineering at Medtronic Diabetes, where he played a role in enhancing manufacturing processes and ensuring product quality. He also served as vice president of manufacturing and quality engineering and senior director of product engineering at Advanced Bionics.
“We are thrilled to welcome Arthur Rascon to the full-time leadership team,” says Tarek Makansi, PhD, president and chief technology officer of StimAire, in a release. “Arthur will move our company and product forward from a demonstrated technology to a certified medical device offering with the goal of improving the lives of those affected by obstructive sleep apnea.”
Rascon adds in a release, “I am deeply impressed with StimAire’s ultra-tiny injectable neuromodulation device, which already has human data supporting efficacy and safety. The path to a successful product is very clear to me, and the recent Breakthrough Device Designation from the FDA will accelerate our progress.”
StimAire recently completed its first-in-human study of its injectable stimulator for OSA.
StimAire is a portfolio company of University Associates Venture Capital.
Photo 324139763 © Nastassia Samal | Dreamstime.com
